Novo Nordisk announce that Saxenda® (liraglutide 3 mg) is now available in the United States (US). Saxenda® is the first glucagon-like peptide-1 (GLP-1) receptor agonist for weight management, approved in the US, EU and Canada
Lixisenatide and liraglutide improved glycemic control in optimized insulin glargine-treated T2D albeit with contrasting mechanisms of action and differing safety profiles (Diabetes Care)
Older age and non-metformin use were associated with more significant GISE leading to discontinuation of liraglutide treatment. The reasons for these findings are unclear and warrant further investigation (Diabetes Research and Clinical Practice)
Novo Nordisk announce that the European Commission has granted marketing authorisation for Saxenda® (liraglutide 3mg) for the treatment of obesity. The authorisation covers all 28 European Union (EU) member states.
Novo Nordisk announce that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted a positive opinion for the use of Saxenda® (liraglutide 3 mg) for the treatment of obesity